Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Taisho Postpones Some R&D Spending Due to Development Delays
November 22, 2004
- PhRMA Publishes Japanese Version of Principles for Conducting Clinical Trials
November 15, 2004
- OTC NEWS IN BRIEF
November 15, 2004
- Mediceo HD Forms Capital Tie-up with Chain Management
November 15, 2004
- MEDICAL DEVICE NEWS IN BRIEF
November 15, 2004
- Tokyo CRO Establishes Its Subsidiary Tokyo CSO
November 15, 2004
- Yamanouchi: Net Profits Down 30.9% due to One-time Costs Related to Merger
November 15, 2004
- BUSINESS NEWS IN BRIEF
November 15, 2004
- Fujisawa: Sales Up 4.1% to \204.5 Bil.
November 15, 2004
- Micardis Slows Progression of Nephropathy in Type 2 Diabetic Patients: Prof. Barnett
November 15, 2004
- WEBSITE NEWS
November 15, 2004
- Semiannual Business Results
November 15, 2004
- Iryo Proverbs Reveal Japanese Spirit (24)
November 15, 2004
- Generic, Switch-OTC PPIs Threaten Sales of Pariet in US: Eisai
November 15, 2004
- BULLETIN
November 15, 2004
- Business Outlook Improving for MPC: Mr Komine
November 15, 2004
- Free-price System for Innovative Drugs Is One Option: Dr Fujii
November 15, 2004
- Shionogi: Profits Up Sharply Despite Decline in Sales
November 15, 2004
- Korosho Withdraws Recommendations for Antibiotics Skin Tests: Safety Info
November 15, 2004
- Santen: Sales Down 2.3% to \45.0 Bil.
November 15, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…